Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusen Pharmaceutical has received approval from China’s National Medical Products Administration to market its Acetylcysteine Effervescent Tablet for treating chronic respiratory diseases like COPD. This approval positions Fusen to capitalize on a substantial market, with the tablet offering benefits such as reduced gastrointestinal irritation and improved patient compliance. The product enriches Fusen’s lineup in respiratory care, aligning with medical guidelines and promising safety and efficacy comparable to existing treatments.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.